Showing results (761-770 of 999) with videos related to

Sort By:
Pageof 100
Circulation|June 28, 2022
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyPaul M Ridker, Nader Rifai, Jean MacFadyen, et al.
Cardiovascular Drugs and Therapy|February 1, 2021
Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare SystemXiaoming Jia, Michelle T Lee, David J Ramsey, et al.
JACC. Heart Failure|March 7, 2023
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC StudyXiaoming Jia, Mahmoud Al Rifai, Chiadi E Ndumele, et al.
The New England Journal of Medicine|March 25, 2026
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor EnlicitideAnn Marie Navar, Elina Mikhailova, Alberico L Catapano, et al.
American Journal of Preventive Cardiology|July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOVAdam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Journal of Preventive Cardiology|August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Heart Journal|June 7, 2016
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)Rishi Puri, Steven E Nissen, Ransi Somaratne, et al.
The New England Journal of Medicine|March 17, 2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular eventsMarc S Sabatine, Robert P Giugliano, Stephen D Wiviott, et al.
Circulation|December 1, 2011
Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) StudySalim S Virani, Ariel Brautbar, Brian C Davis, et al.
The American Journal of Cardiology|September 1, 1996
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid RegistryC M Ballantyne, R C Bourge, L J Domalik, et al.
Pageof 100